\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe European Commission and New Zealand have concluded the association negotiations of New Zealand to Horizon Europe. New Zealand will become the first non-EU industrialized country that will be associated to Horizon Europe. The association agreement is expected to be signed in the coming months. New Zealand will only associate to Pillar 2 of Horizon Europe. This new development resulted in an update of the list of participating countries in Horizon Europe in the Horizon Europe Programme Guide. New Zealand is now considered as a country in view of association and therefore the transitional arrangements will apply. As from the Work Programmes 2023 onwards, New Zealand partners requesting EU funding have to be included as beneficiaries in proposals of Horizon Europe Pillar 2 calls. Please be aware that if at the time of the signature of the grant agreement of the project, the association agreement of New Zealand has not been finalised yet then the status of the New Zealand partner will need to be changed to associated partner and will not be funded through Horizon Europe. In this case the New Zealand partners will need to secure their own funding.
More information on association and international cooperation to Horizon Europe can be found in this infosheet.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
